We are live on ! Find out more
EUCR

Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR

Delisted

EUCR was delisted on the 26th of April, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of EUCR yet.

EUCR Hedge Fund Activity: Q2 2023 in Review

0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q2 2023, worth a combined $0 — down 100% from $2.99M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of EUCR and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.03M sold.

  • 0 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q2 2023, down from 4 in Q1 2023.
  • Funds reported $0 of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q2 2023 and 4 closed out, a net change of -4 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q2 2023 was EcoR1 Capital, an estimated $2.03M sold.

Based on aggregated 13F filings for Q2 2023.